| Company | Value | Change | %Change |
|---|
This new product is bioequivalent and therapeutically equivalent to the reference-listed drug, Evoclin Foam, 1%, manufactured by Mylan Pharmaceuticals Inc, Glenmark Pharma said in a stock exchange filing.
Clindamycin Phosphate Foam, 1% is indicated for the treatment of acne vulgaris, providing an effective solution for patients seeking topical treatment options. Glenmark’s product offering mirrors the clinical efficacy of Evoclin Foam, with the added benefit of affordability for patients and healthcare providers alike.
According to IQVIATM sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately USD 5.8 million. This market data reflects strong demand for effective acne treatments, signaling a promising opportunity for Glenmark’s latest product, the company said.Earlier Glenmark, in partnership with Cosmo Pharmaceuticals N.V., obtained clearance from the UK Medicines and Healthcare Products Regulatory Agency to market Winlevi, a cream for treating acne.
As a part of the agreement signed in September 2023, Glenmark in-licenced the product from Cosmo Pharmaceuticals for distribution across Europe and South Africa.
Shares of Glenmark were trading 2.93% lower at ₹1,410 apiece on the BSE around 9.57 am.
